Why is "Repotrectinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-18 15:17:31
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Repotrectinib entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-18 and was most recently seen on 2026-07-18.
Wikipedia Overview
Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations - The ASCO Post
-
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial - Nature
-
Current and Emerging Treatment Strategies for Advanced ROS1 -Positive NSCLC - Cancer Therapy Advisor
-
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC - OncLive
-
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China - Pharmaceutical Technology
-
FDA Approves Repotrectinib in NTRK-Positive Solid Tumors - Targeted Oncology
-
FDA Grants Accelerated Approval to Repotrectinib for Cancers with NTRK Fusions - Memorial Sloan Kettering Cancer Center
-
Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs - ASCO Daily News
-
Bristol Myers Squibb: Augtyro Listed on PBS for ROS1-Positive NSCLC - Oncodaily
-
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - National Cancer Institute (.gov)
-
AUGTYRO (Repotrectinib) for the Treatment of ROS1 -Positive Non-Small Cell Lung Cancer - Journal of Hematology Oncology Pharmacy
-
Exposure–Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors - Wiley & Sons
-
FDA Approves Repotrectinib in ROS1-Positive NSCLC - Oncology News Central
-
Repotrectinib for ROS1 Fusion–Positive Advanced NSCLC - The ASCO Post
-
Repotrectinib (Augtyro) 2025 Updates: Uses in Cancer, Side effects, Dosage, Expectations and more - Oncodaily
-
Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid Tumors - OncLive
-
Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC - OncLive
-
Repotrectinib (Augtyro) Patients Guide for 2025: Targeted Therapy for ROS1 and NTRK positive Tumors - Oncodaily
-
Dr Bestvina on the Management of AEs Associated With Repotrectinib in ROS1+ NSCLC - OncLive
-
Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward - OncLive
-
Treatment of ROS1+ NSCLC with Augtyro (repotrectinib) - news.cancerconnect.com
-
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC - OncLive
-
Repotrectinib Approved for Adults and Children with NTRK-mutated Cancer - American Association for Cancer Research (AACR)
-
EMA Validates MAA for Repotrectinib in ROS1+ NSCLC and NTRK+ Solid Tumors - OncLive
-
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC - Targeted Oncology
-
EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors - CancerNetwork
-
2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib - OncLive
-
Repotrectinib in ROS1 Fusion–Positive Lung Cancer - The New England Journal of Medicine
-
FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors - The ASCO Post
-
Repotrectinib effective in ROS1-fusion-positive NSCLC - Nature
-
FDA Approves Repotrectinib for Certain Solid Tumors - Oncology News Central
-
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC - The American Journal of Managed Care
-
Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC - OncLive
-
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells - Nature
-
FDA Grants Accelerated Approval to Repotrectinib for NTRK+ Solid Tumors - OncLive
-
Assessing Frontline TKIs and Treatment Considerations in ROS1-Positive Advanced NSCLC - OncLive
-
Repotrectinib Plus Osimertinib Under Study in EGFR-Mutant NSCLC - OncLive
-
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer - Wiley Online Library
-
FDA Approves New Drug for Non-Small Cell Lung Cancer With ROS1 Fusions - Memorial Sloan Kettering Cancer Center
-
Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLC - OncLive
-
Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies - CancerNetwork
-
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers - Nature
-
Bristol Myers' $4.1B Turning Point buy yields FDA approval for lung cancer drug Augtyro - Fierce Pharma
-
FDA grants accelerated approval of targeted therapy for adults and children with NTRK fusion cancers - UCLA Health
-
New Lung Cancer Drug Augtyro is Now Available - Managed Healthcare Executive
-
BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion - Nature
-
Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC - OncLive
-
Bristol Myers bets $4B on Turning Point and its targeted cancer drugs - BioPharma Dive
-
Current Targeted Therapy Options in ROS1-Positive NSCLC - Pharmacy Times
-
Two Lung Cancer Drugs Recommended by EMA - Medscape
-
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Augtyro for the Treatment of NTRK-Positive Locally Advanced or Metastatic Solid Tumors - Applied Clinical Trials Online
-
UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy - Fierce Biotech
-
FDA Approves Augtyro for Children, Adults With NTRK-Positive Solid Cancers - Cure Today
-
FDA Approves Augtyro for Patients With NSCLC Subset - Cure Today
-
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC - Pharmaceutical Technology
-
BMS Picks up High Potential NSCLC Drug in $4.1B Turning Point Acquisition - BioSpace
-
Augtyro Gets FDA Priority Review for NTRK-Positive Solid Cancers - Cure Today
-
BMS wins Korean nod for Augtyro, joining Roche and Bayer in tumor-agnostic cancer race - Korea Biomedical Review
-
Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics - PMLiVE
-
Augtyro Approved in NTRK-Positive Cancers, Pediatric Research Continues - Cure Today
-
Turning Point Therapeutics eyes $100M IPO to propel treatment for drug-resistant tumors - Fierce Biotech
-
First- and Second-Generation TRK Inhibitors Show Promise in TRK Fusion+ Thyroid Cancer - Targeted Oncology
-
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - PR Newswire
-
BMS’ Augtyro Wins FDA Accelerated Approval for NTRK-Positive Solid Tumors - BioSpace
-
Bristol Myers Squibb to Acquire Turning Point Therapeutics - citybiz
-
FDA widens label for BMS’ cancer drug Augtyro - pharmaphorum
-
Bristol Myers Squibb Wins FDA Approval for Lung Cancer Drug From $4B Deal - MedCity News
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.